Abstract Purpose: Chromosomal microarray (CMA) testing provides the highest diagnostic yield for clinical testing of patients with developmental delay (DD), intellectual disability (ID), multiple ...

Explore the booming Chromosomal Microarray Market, projected to grow from USD 1.69 Billion in 2025 to USD 3.32 Billion by 2034, at a 10.2% CAGR. Driven by demand for advanced genetic diagnostics ...

“Thermo Fisher’s unparalleled commitment to driving innovation in chromosomal microarrays has led to advancement of cytogenetic testing capabilities,” said Kevin Lowitz, vice president and ...

A large study from Children's Hospital Boston and the Boston-based Autism Consortium finds that a genetic test that samples the entire genome, known as chromosomal microarray analysis, has about ...

Noninvasive prenatal testing detected 83.2 percent of chromosomal abnormalities normally picked up by invasive diagnostic testing strategies, such as chorionic villus sampling or amniocentesis.

Sequenom, Inc. SQNM, a life sciences company providing innovative diagnostic testing and genetic analysis solutions, and CombiMatrix Corporation CBMX, a molecular diagnostics laboratory performing ...

For prenatal testing, CombiMatrix uses its single nucleotide polymorphism (SNP)-based CombiSNP array technology to provide a comprehensive look at the genetic makeup of the unborn fetus by testing ...

Worldwide sales of Chromosomal Microarray Market are expected to grow at a significant CAGR of 10.2%, reaching USD 3.32 Billion by the end of the forecast period in 2034.

Thermo Fisher Scientific Inc., announced that the Applied Biosystems™ CytoScan™ Dx Assay and Applied Biosystems™ Chromosomal Analysis Suite (ChAS) Dx software now comply with In Vitro Diagnostic ...